期刊文献+

生物可降解聚合物支架与永久聚合物支架治疗冠心病的随访研究 被引量:2

Clinical follow-up of biodegradable polygmer stents (EXCEL) and durable polymer stents (CYPHER) in treating coronary artery disease
下载PDF
导出
摘要 目的:比较国产生物可降解希罗莫司支架(EXCEL)与进口永久聚合物希罗莫司支架(CYPHER)在冠心病患者中应用的安全性及有效性。方法:回顾分析同期植入EXCEL支架治疗的230例和植入CYPHER支架的161例冠心病患者,对比分析两组患者PCI操作成功率、术后1年内主要不良心脏事件(MACE)发生率及支架内血栓事件发生率。结果:两组在基本临床情况、冠脉病变特征及主要介入技术指标等方面均无统计学差异;两组手术操作成功率分别为99.6%和99.4%;术后随访1年MACE发生率EXCEL组(5.8%)略高于CYPHER组(4.6%),但两组比较差异无统计学意义(P>0.05);CYPHER组支架内血栓事件发生率0.7%,而EXCEL组术后无支架内血栓事件发生,但两组比较差异无统计学意义(P>0.05)。结论:生物可降解希罗莫司涂层支架(EXCEL)治疗冠心病安全有效,各项指标与CYPHER支架相比无明显差异。 Objective:To compare the safety and efficacy of biodegradable polymer sirolimus-eluring stent (EXCEL) and durable polymer sirolimus-eluting stents (CYPHER) in the treatment for coronary artery disease. Methods: This is a retrospective case-control study in a single centre. A cohort of 230 patients with CAD treated with EXCEL stent and a subset of 161 CAD patients treated with CYPHER stent from January 2007 to April 2008 were followed up. The results from 12 months of follow- up were analyzed by comparing procedural success rate, MACE and stent thrombosis. Results: Two groups were similar in main baseline clinical data and major angiography characteristics. The procedural success rate was 99.6% in EXCEL group and 99.4% in CYPHER group, respectively (P〉0.05). The incidence of MACE at one-year follow-up was 5. 8% in EXCEL group and 4.6% in CYPHER group (P〉 0.05). Stent thrombosis occurred in 1 patient (0.7%) in CYPHER group and in no patient in EXCEL group, without significant difference (P〉0.05). Conclusion:Implantation of the EXCEL stent in patients with coronary artery disease is safe and effective, with no difference compared with that of the CYPHER stent in one-year follow-up outcomes.
出处 《国际心血管病杂志》 2010年第3期183-185,共3页 International Journal of Cardiovascular Disease
关键词 EXCEL支架 CYPHER支架 冠状动脉粥样硬化性心脏病 EXCEL stent CYPHER stent Coronary artery disease
  • 相关文献

参考文献11

  • 1Korovesis S, Karvouni E, Giazitzoglou E, et al. Drug-eluting stents: immediate and long term results[J]. Hellenic J Car diol,2005, 46( 5): 3311-335.
  • 2Gao RI., Xu B, Lu SZ,et al. Safety and efficacy of the CY PHER Select Sirolimus-eluting stent in the "Real World"- clinical and angiographie results from the China CYPHER Se lect registry[J].Int J Cardiol, 2008,125(3): 339-346.
  • 3吕树铮,陈韵岱,陈欣,陈立伟,柳宏,孟康,宋现涛,田锐,金泽宁,陈立颖,孙海燕,颜冬,吴小凡,葛长江.真实临床条件下Cypher^(TM)支架的应用效果评价[J].中国介入心脏病学杂志,2005,13(2):67-70. 被引量:10
  • 4Cutlip DE, Windecker S, Mehran R, et al. Clinical end point in coronary stent trials: a case for standardized definitions [J].Circulation, 2007,]15(17):2344 2351.
  • 5经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志,2009,37(1):4-25. 被引量:542
  • 6Takahashi S, Kaneda H, Tanaka S, et al. Late gngiographic stent thrombisis after sirolimus-eluting stent implantation [J]. Circ J,2007,71(2):226-228.
  • 7王海容,邱建平,沈卫峰.极晚期雷帕霉素药物洗脱支架内血栓形成1例[J].国际心血管病杂志,2008,35(1):55-55. 被引量:1
  • 8Makino Y, Hosoda H, Shibata K, et al. Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy[J]. Hypertension, 2002,39 (3) :781-784.
  • 9Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and la'te thrombofc risk[J]. J Am Coil Cardiol,2006,48 ( 1 ) :193-202.
  • 10Ge J, Qian J, Wang X, et al. Effectiveness and safety of the sirolimus- eluting stents coated with bioabsorbable polymer coating in human coronary arteries[J]. Catheter Cardiovasc Interv, 2007,69(2): 198- 202.

二级参考文献12

  • 1陈纪林,高润霖,杨跃进,乔树宾,秦学文,姚民,刘海波,吴永健,袁晋青,陈珏,徐波.雷帕霉素药物洗脱支架在冠心病复杂病变中应用的近远期疗效[J].中华心血管病杂志,2004,32(10):867-869. 被引量:28
  • 2CHANCE研究组.无保护左主干病变支架置入术预后及影响因素的分析——中国无保护左主干病变支架置入术注册(CHANCE)研究[J].中华心血管病杂志,2005,33(3):210-215. 被引量:18
  • 3Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59
  • 4Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 2004, 109: 1244-1249.
  • 5Tanabe K, Hoye A, Lemos PA, el al. Restonosis rates following bifurcation stenting with sirolimus-eluting stents for De Novo narrowings. Am J Cardiol, 2004,91 : 115-118.
  • 6Smith SC, Dove JT, Kennedy JW, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PICA guidelines-executive summary). A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise, the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coil Cardiol, 2001,37:2215-2239.
  • 7Ong AT, Aoki J, Mcfadden EP, et al. Classitication and current treatment options of in-stent restenoses. Present status and future perspectives. Herz, 2004,29: 187-194.
  • 8Leon MB, T eirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenoses after stenting. N Eng J Med, 2001,344:250-256.
  • 9Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenoses in a native coronary artery. N Eng J Med, 2003,349: 1315-1323.
  • 10Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirlimus-eluting stents compared with conventional bare stent implantation in the real world: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (REASERCH) Registry.Circulation, 2004,109; 190-195.

共引文献550

同被引文献36

  • 1Moses JW,Leon MB,Popma JJ,et al.Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery[J].N Engl J Med,2003,349(14):1315-1323.
  • 2Stone GW,Ellis SG,Cox DA,et al.One-year clinical results with the slow-release,polymer-based,paclitaxel-eluting TAXUS stent:the TAXUS-IV trial[J].Circulation,2004,109(16):1942-1947.
  • 3Takahashi S,Kaneda H,Tanaka S,et al.Late angiographic stent thrombosis after Sirolimus-Eluting stent implantation[J].Circ J,2007,71(2):226-228.
  • 4Liistro F,Colombo A.Late acute thrombosis after paclitaxel eluting stent implantation[J].Heart,2001,86(3):262-264.
  • 5Virmani R,Liistro F,Stankovic G,et al.Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans[J].Circulation,2002,106(21):2649-2651.
  • 6Virmani R,Gnagliumi G,Farb A,et al.Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent:should we be cautious?[J].Circulation,2004,109(6):701-705.
  • 7Gao Run-lin,Han Ya-ling,Yan Xin-chun,et al.A prospective multicenter randomized trial of PROSTENT bioabsorbable polymer vs.FIREBIRD durable polymer sirolimus-eluting stent:9-month angiographic and 12month clinical results[J].J Am Coll Cardiol,2010,56:55B.
  • 8Xu Bo,Dou Ke-fei,Han Ya-ling,et al.A prospective,multicenter clinical trial of TIVOLI bioabsorbable polymer based sirolimus-eluting vs.ENDEAVOR zotarolimuseluting stert in patients with coronary artery disease:8-month angiographic and l-year clinical follow-up results[J].Am J Cardiol,2009,104:152D.
  • 9Cutlip DE,Windecker S,Mehran M,et al.Clinical end points in coronary stent trials:a case for standardized cdefinition[J].Circulation,2007,115(17):2344-2351.
  • 10Windecker S,Serruys PW,Wandel S,et al.Biolimuseluting stent with biodegradable polymer versus sirolimuseluting stent with durable polymer for coronary revascularisation(LEADERS):a randomised non-inferiority trial.[J].Lancet,2008,372(9644):1163-1173.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部